Key terms
About NRSN
Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company. The firm is focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. It is involved in the 2b/3 clinical trial using its product candidate, PrimeC in patients with ALS and also commencing research into other possible indications for the drug, including Alzheimer’s and Parkinson’s diseases. The company was founded by Alon Ben-Noon on February 13, 2017 and is headquartered in Herzliya, Israel.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest NRSN news
Apr 22
8:32am ET
NeuroSense and Genetika+ to collaborate in drug development for Alzheimer’s
Apr 18
8:34am ET
NeuroSense reports Phase 2b neurology results of PrimeC
Apr 12
5:28pm ET
NeuroSense Launches Pre-Funded Warrants Offering
Apr 10
7:24pm ET
NeuroSense prices $4.5M registered direct offering at $1.50 per share
Apr 09
8:57am ET
NeuroSense Partners with Lonza on ALS Biomarker Research
Apr 05
10:28am ET
NeuroSense’s Positive ALS Trial Results and 2023 Finances
Feb 21
8:32am ET
NeuroSense reports additional data from its Phase 2b PARADIGM trial of PrimeC
Feb 07
9:29am ET
NeuroSense regains compliance with NASDAQ listing rules
No recent press releases are available for NRSN
NRSN Financials
Key terms
Ad Feedback
NRSN Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
NRSN Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
